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A monoclonal antibody against subfragment 2 (S-2) of smooth muscle myosin, designated MM-9, was generated and characterized. MM-9 potently 
inhibited subfragment 1 (S-l) release by papain proteolysis of myosin, suggesting that the epitope of MM-9 is at or very close to the S-l/S-2 junction. 
The depression of CaZ+- and Mg2+ -ATPase activities of myosin at low ionic strength was significantly reduced by MM-9. MM-9 increased the 
acto dephosphorylated HMM ATPase activity about 3-fold. On the other hand, the antibody had no effect on the KCl-dependence of viscosity 
of monomeric myosin. These results suggest that the folding of the myosin rod is not the direct determinant of enzymatic activity, and that the 
subtle conformational change at the S-l/S-2 junction (head-neck region) plays a critical role in determining enzymatic activities. 
Monoclonal antibody; Smooth muscle myosin conformation; Subfragment 2 
1. INTRODUCTION 
Smooth muscle myosin [l-3] and myosin from 
several non-muscle sources [3-51 forms a folded struc- 
ture (10 S) that dramatically alters its hydrodynamic 
properties. Under certain conditions it undergoes a 
large conformational change to an extended form (6 S), 
and this transition is characterized by distinct en- 
zymatic properties [6]. A high concentration of Mg2+ 
favors the 6 S conformation and causes tension 
development in skinned smooth muscle fibers in the 
absence of phosphorylation [7]. These findings led to 
the ‘shape-activity’ hypothesis that the 10 S-6 S transi- 
tion could be a component of the regulatory 
mechanism in smooth muscle myosin. However, it is 
unlikely that a large conformational change is in fact 
essential in determining enzymatic activity. Some subtle 
conformational change in the S-l/S-2 junction may be 
more important because of the following evidence: (1) 
the resistance to the proteolysis at the S-l/S-2 junction 
but not the LMM/HMM junction was markedly 
altered with the conformational transition of myosin 
[8,9]; (2) the actin-activated ATPase activity of S-l, 
which retains a phosphorylatable light chain, is not 
regulated by phosphorylation while HMM, even 
though it does not form a folded structure, was 
regulated by phosphorylation [9]; (3) the change in the 
digestability at the S-l/S-2 junction, which accom- 
panies the 10 S-6 S transition, also markedly differed 
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between phosphorylated and dephosphorylated HMM 
[gl. 
Recently we generated a monoclonal antibody 
against the 17 kDa light chain of smooth muscle 
myosin, and it was found that the antibody, which in- 
hibited the conformational change of smooth muscle 
myosin, markedly activated actin-activated ATPases 
[lo]. Trybus et al. reported that the regulatory light 
chain deficient myosin was unable to form the folded 
monomer [l 11. Taken together, this evidence suggests 
the spatial relationship between the heads, including 
the two light chains, and S-2 at the S-l/S-2 junction 
would play an important role in the conformational 
change. 
In this paper, we investigated the effect of a 
monoclonal antibody against S-2 region on the 
hydrodynamic property and enzymatic activity of 
smooth muscle myosin. This antibody may provide new 
insight into the function of S-2, which still remains un- 
solved. 
2. MATERIALS AND METHODS 
2.1. Proteins 
Myosin [12] and MLCK [13] were prepared from turkey gizzard. 
Calmodulin [14] and F-actin [15] were prepared from bull testes and 
rabbit, respectively. HMM and S-l were prepared using S. aureus 
protease as described previously [9]. 
2.2. Production of monoclonal antibodies 
The production and characterization of antibodies were done as 
described previously [lo]. MM-9 and MM-6 were grown in ascitic 
fluid and purified with ammonium sulfate precipitation followed by 
DEAE-cellulose chromatography [16]. 
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2.3. Others 
ATPase activity was measured as described previously [9]. Viscosi- 
ty was measured with a Cannon-Ubbelohde viscometer with a water 
flow time of approximately 54 s. Electrophoresis was carried out on 
a 7.5-20% polyacrylamide gradient slab gel using the discontinuous 
buffer system of Laemmli [17]. lmmunoblotting was carried out ac- 
cording to the method of Towbin et al. [18]. ELISA, electron 
micrograph (rotary shadowing) of myosin/antibody complex and im- 
munoaffinity column were performed as described previously [lo]. 
Molecular masses were estimated using the following standard: 
smooth muscle myosin heavy chain (200000), fl-galactosidase 
(116000), phosphorylase b (97000), bovine serum albumin (66000), 
ovalbumin (45000), carbonic anhydrase (29000), trypsin inhibitor 
(20100), and lysozyme (14300). 
3. RESULTS AND DISCUSSION 
We produced a monoclonal antibody against gizzard 
smooth muscle myosin, designated MM-9 (IgGi, k light 
chain). ELISA and immunoblot data (Fig. 1) suggest 
that MM-9 recognizes subfragment 2 (S-2) of smooth 
muscle myosin. Electron micrograph (rotary shadow- 
ing) of myosin/MM-9 complex showed that MM-9 
binds at or near the head/rod junction (not shown). 
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Fig. 1. Identification of the epitope of MM-9. (A) ELISA of MM-9. 
(w) Whole myosin; (-) S-l (94 kDa native S-l heavy chain 
is cleaved into 68 kDa and 26 kDa fragments by SAP digestion (see 
references in [9]); (U) HMM. 1 pg of protein was precoated on 
96 wells. Inset shows the SDS-PAGE and immunoblot of the 
fractions from MM-9 affinity column. Gizzard smooth muscle 
myosin digested by SAP was passed through MM-9 affinity column 
(see section 2). The flow-through fraction was S-l (lane a) and bound 
protein was revealed to be HMM plus S-2 fragments (lane b). The 
latter sample was electrophoresed and transferred to the 
nitrocellulose membrane. Amido black staining of sample showed 
130-, 126-, 68-, 62-, 5%, 36-, 32-kDa peptides and two light chains of 
20- and 17.kDa (not shown). Since MM-9 bound to both the 32- and 
36-kDa proteins (both bands were referred to as S-2) and both the 58- 
and 62-kDa proteins (S-2 plus 26-kDa peptide of S-l) (lane c), the 
epitope of MM-9 is not located at the C-terminus 4-kDa peptide of 
S-2 (see references in [9]). 
Furthermore, MM-9 potently inhibited the S-l release 
by papain digestion of smooth muscle myosin, in- 
dicating that the epitope of MM-9 is very close to the 
S-l/S-2 junction (Fig. 2). 
Recently we reported a monoclonal antibody against 
the 17-kDa light chain (MM-2), which inhibits the 6 S 
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Fig. 2. The effect of MM-9 on S-l release by papain digestion of 
smooth muscle myosin. (A) The elution profile of digests of myosin 
by papain. Myosin (600 @g/ml) in 0.5 M NaCl, 30 mM Tris-HCl, pH 
7.5, in the absence or presence of MM-9 (300ag/ml) was digested by 
papain (1:40 papain/myosin (w/w)) for 5 min at 25”C, and the 
reaction was stopped with 5 mM iodoacetic acid. 1 ml of sample was 
applied to a TSK SW4000 column and eluted at a flow rate of 
0.6 ml/fraction. (M) Protein concentration determined by a dye 
binding method [19]; (- ) Ca’+-ATPase activity of the fractions. 
Assay conditions for ATPase activity: 0.5 M KCl, 50 mM Tris-HCl, 
pH 7.5, and 10 mM CaClz. (B) SDS-PAGE profiles of the fractions. 
The 1st and 20th lanes show molecular weight standards. The 
2nd-10th lanes correspond to fractions 11-14 and 18-22 of left 
panel of A (minus MM-9), respectively. The llth-19th lanes 
correspond to fractions 11-14 and 18-22 of right panel of A (plus 
MM-9), respectively. 
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to 10 S conformational change and increases the V,,, 
of acto-ATPase activity of dephosphorylated myosin 
about lo-fold [ 121. The epitope of MM-2 was located 
very near the S-l/S-2 junction (51 -t 25 A from the 
head/rod junction) judged from rotary shadowing of 
electron microscopy. Therefore, it is of interest to ex- 
amine whether MM-g, which recognizes a part of S-2 of 
myosin molecule close to the S-l/S-2 junction, affects 
the 10 S-6 S transition of smooth muscle myosin and 
ATPase activity. Fig. 3 shows the effects of MM-9 on 
the KC1 dependence of Ca’+- and Mg’+-ATPase ac- 
tivities of smooth muscle myosin. As is shown 
previously [6], both Ca2+-, and Mg’+-ATPase activities 
in the absence of the antibody were markedly depressed 
below 0.3 M KCI. It was shown previously [6] that this 
was accompanied by the conformational transition of 
myosin from 6 S to 10 S. In the presence of MM-g, the 
depression of ATPase activities below 0.3 M KC1 was 
significantly reduced although the activities were still 
decreased below 0.3 M KCI. The effect of MM-9 on the 
conformational transition of myosin was monitored by 
viscosity measurements (Fig. 4). The relative viscosity 
of myosin was markedly reduced below 0.3 M KC1 and 
it was shown previously [6] that this is due to the 
change in the conformation from 6 S to 10 S (the 
folding of the tail portion of the molecule). MM-9 did 
not affect the viscosity change of myosin (Fig. 4), and 
therefore this suggests that MM-9 does not inhibit the 
large conformational change, i.e. the folding of the tail 
portion of the molecule. We have proposed that some 
subtle conformational change in the head/rod junction 
is the determinant of ATPase activity of myosin (see 
section 1). The effects of MM-9 can be explained as 
follows. MM-9 binds at the head/rod junction and af- 
fects the conformation at the head/rod junction. This 
does not interfere to form a folded structure (Fig. 4); 
however, it significantly abolishes the depression of 
ATPase activity of myosin (Fig. 3). That is, MM-9 
altered the conformation at the head/rod junction of 
myosin and this conformational change was significant 
enough to alter the ATPase activity of myosin, but not 
enough to alter the folded structure to the extended 
one. 
The effects of MM-9 on the actin-activated 
Mg’+-ATPase activity for dephosphorylated HMM 
were examined (Fig. 5). I’,,,,, of the actin-activated AT- 
Pase activity was increased 3.2 times and Ka,-tin was 
decreased 2 times by MM-g. Recently, we reported a 
monoclonal antibody aginst the 17-kDa light chain 
(MM-2) which inhibits the formation of a folded struc- 
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Fig. 3. The effect of MM-9 on KC1 dependence of ATPase activities 
of myosin. Ca’+-ATPase activity (o,o) and Mg’+-ATPase activity 
(A, A). Assay conditions: dephosphorylated myosin (120 &ml), 
50 mM Tris-HCl, pH 7.5, and 10 mM CaCll or 1 mM MgC12 in the 
absence of (0, A) or presence (0, A) of MM-9 (60 pg/ml). 
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Fig. 4. The effect of MM-9 on the viscosity of monomeric myosin. 
Viscosity of myosin was measured in the solution containing myosin 
(0.5 mg/ml), various concentrations of KCI, 30 mM Tris-HCI, pH 
7.5, 1 mM MgC12, 1 mM ATP at 23°C. Control (0); MM-9 
(0.25 mg/ml, n ); MM-6 (anti-S-l, 0.3 mg/ml, A). Values are the 
mean of 4 measurements. 
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Fig. 5. The effect of MM-9 on the actin-activated Mg’+-ATPase 
activity of dephosphorylated HMM. Assay conditions: 100 /rg/ml, 
50 mM KCl, 30 mM Tris-HCl, pH 7.5, 1 mM EGTA and 1 mM 
[y-“P]ATP. The reaction was started by the addition of actin (0) or 
actin plus 2 molar excess of MM-9 (0). The scales of the ordinate 
are different for (0) and (0). The ATPase activity of myosin alone 
was subtracted from the total activity. 
ture (10 S) and increases the l/m,, of actin-activated 
ATPase activity of dephosphorylated myosin and 
HMM about 15-20 times [lo]. Although the activation 
observed using MM-9 was significant, the activation 
was not as dramatic as MM-2. The change in the con- 
formation of myosin by MM-9 is probably not suffi- 
cient to achieve the active conformation for the 
following reason. The inhibition of the depression of 
the Ca’+ - and Mg2+-ATPase activity of myosin MM-9 
at below 0.3 M KC1 was not as complete as by MM-2 
(Fig. 3). The activation of the actin-activated ATPase 
activity by MM-9 was not as large as by MM-2 (Fig. 5). 
MM-9 does not inhibit the formation of a folded struc- 
ture (Fig. 4). Although the activity change was not 
complete since the ATPase activities were significantly 
affected by MM-g, but the global change in the confor- 
mation (10 S-6 S) was not, it can be concluded that the 
global change in the conformation is not the direct 
determinant of ATPase activity. A more subtle change 
in the conformation at the head/rod junction is likely 
to determine the ATPase activity and this subsequently 
induces the large change in the myosin conformation 
and forms 10 S and 6 S structures. 
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